Stempoint Capital’s AC Immune ACIU Stock Holding History

Stempoint Capital’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-434,588	Closed	-$2.17M	–	63
2023 Q4	$2.17M	Buy	+434,588	New	+$1.4M	0.58%	49

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Stempoint Capital's ACIU Position: Q1 2024 in Review

Stempoint Capital sold out of AC Immune (ACIU) in Q1 2024, closing a stake of 434,588 shares — an estimated $2.17M sold.

Stempoint Capital first reported a position in ACIU in Q4 2023 and held it in 1 quarter. The position peaked at $2.17M in Q4 2023. 37 funds tracked by Wall St. Rank hold ACIU as of Q1 2024.

Stempoint Capital reported no remaining AC Immune position as of Q1 2024 after selling out during the quarter.
Stempoint Capital sold 434,588 AC Immune shares in Q1 2024, an estimated $2.17M.
Stempoint Capital first reported a position in AC Immune in Q4 2023 and held it in 1 quarter.
Stempoint Capital's AC Immune position peaked at $2.17M in Q4 2023.
37 funds tracked by Wall St. Rank held AC Immune as of Q1 2024.

Based on Stempoint Capital's 13F filing for Q1 2024, filed 14 May 2024.